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Abstract: Age-related macular degeneration (AMD) is a major cause of severe visual loss 
worldwide. Neovascular (wet) AMD accounts for 90% of the visual loss associated with the 
disorder and vascular endothelial growth factor (VEGF) has been shown to play a major role in 
neovascularization and vascular permeability, the major causes of visual loss in AMD, making 
it an ideal target for therapeutic intervention. To utilize this strategy, pegaptanib, an aptamer 
that specifically binds to and blocks VEGF165, the VEGF isoform primarily responsible for 
abnormal vascular growth and permeability in AMD, was developed. Following encouraging 
preclinical trials, clinical trials showed that pegaptanib stabilized vision and reduced the risk 
of severe visual loss in the majority of patients with AMD, with some patients showing visual 
improvement. Pegaptanib has maintained a good safety profile with only occasional adverse 
effects. Even greater success was achieved when pegaptanib was used in combination with 
another therapeutic strategy, such as photodynamic therapy or bevacizumab, a pan isoform 
VEGF inhibitor. Further investigation of pegaptanib for the therapy of wet AMD, particularly 
in combination with other modes of therapy, should be encouraged.
Keywords: age-related macular degeneration, pegaptanib, vascular endothelial growth factor, 
choroidal neovascularization, macular edema
Introduction
Age-related macular degeneration (AMD) is the leading cause of irreversible, severe 
visual loss in people aged 55 and older in the developed world (Congdon et al 2004) and 
it is estimated that more than 500 000 people worldwide lose their sight annually from 
the disease (Eyetech Pharmaceuticals, Inc. 2005). The neovascular (wet) form of the 
disease accounts for only 10% of the total incidence of the disease, but is responsible 
for 90% of the severe visual loss associated with the disease (Ferris et al 1984). Within 
the next 5 years, it is expected to affect almost 1 million people in the USA, posing a 
severe health issue (Bressler et al 2003) and having a major impact on the quality of 
life for the elderly, due to difficulties in performing routine tasks (Dong et al 2004). 
Wet AMD is characterized by choroidal neovascularization (CNV) that penetrates 
Bruch’s membrane and invades the subretinal space, often leading to exudation and 
hemorrhage (Green 1999; Pauleikhoff 2005). If left untreated, damage results to the 
photoreceptors leading to loss of central vision and eventually the vessels are largely 
replaced by a fibrovascular scar (Green 1999). The visual prognosis is variable, based 
on lesion location, composition, and size (Pauleikhoff 2005).
Other factors are involved, but it is clear that vascular endothelial growth factor 
(VEGF) is a key molecule in the development of CNV . VEGF is regulated by hypoxia 
and it promotes angiogenesis and vasopermeability, which are characteristic of the 
disorder (D’Amore 1994; Green 1999; Pauleikhoff 2005). VEGF and its mRNA are 
upregulated in CNV associated with AMD (Kvanta et al 1996; Lopez et al 1996; Wells et 
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al 1996) and in experimental models of CNV (Ishibashi et al 
1997; Yi et al 1997). VEGF is critical for experimental CNV 
to develop (Vinores et al 2006) and exposure of choroidal 
vessels to VEGF results in CNV formation (Schwesinger et 
al 2001). Collectively, these data provide a strong rationale 
for targeting VEGF in the treatment of wet AMD. To utilize 
this strategy, pegaptanib (Macugen
®), a 28-base ribonucleic 
acid aptamer, was developed to specifically bind to and 
block the activity of the 165 amino acid isoform of VEGF 
(VEGF165), the major inducer of abnormal blood vessel 
growth and leakage in wet AMD. Pegaptanib has a mean 
apparent half-life in the vitreous of 10 + 4 days (Patel et 
al 2006), but to prolong activity at the site of action, the 
sugar backbone was modified to prevent degradation and 
the aptamer was covalently linked to two branched 20-kD 
polyethylene glycol moieties, which increases its half-life in 
the vitreous (Ruckman et al 1998; Drolet et al 2000). VEGF165 
consists of a receptor-binding domain, which is found on 
all VEGF isoforms, and a heparin-binding domain, which 
is unique to VEGF165 (Ferrara et al 2003). Pegaptanib binds 
to the heparin-binding domain, accounting for its specificity 
for VEGF165, with an extremely high affinity (Kd = 50 pM) 
(Lee et al 2005) and inhibits the interaction of VEGF165 
with its type-1 and type-2 receptors. With cultured human 
umbilical vein endothelial cells, pegaptanib inhibited the 
binding, signal transduction, calcium mobilization, and cell 
proliferation mediated by VEGF165 to an extent comparable 
with anti-VEGF monoclonal antibodies (Bell et al 1999).
Preclinical trials (Table 1)
Based on its vast potential for the treatment of AMD, diabetic 
retinopathy, and tumors, preclinical evaluation of pegaptanib 
was quickly undertaken to determine its safety and efficacy. 
Following intravitreal administration of pegaptanib into 
rhesus monkeys, there were no toxic effects, no change 
in intraocular pressure, and no immune response to the 
aptamer. There was a half-life of the aptamer in the vitreous 
of approximately 90–100 hours, depending on the dose 
administered, and the compound remained fully active in the 
eye for at least 28 days following biweekly injections (Drolet 
et al 2000). Subcutaneous and intravenous administration 
were also effective at maintaining adequate plasma levels 
(Tucker et al 1999), providing a basis for subcutaneous 
delivery of the aptamer. In the Miles assay, pegaptanib almost 
completely blocked VEGF-mediated vascular leakage and 
inhibited corneal angiogenesis by 65% in a rat model and 
retinal neovascularization in a murine model of retinopathy 
of prematurity (Eyetech Study Group 2002). In diabetic rats, 
pegaptanib significantly suppressed leukostasis and vascular 
leakage in both the early and late stages of the disease 
(Ishida et al 2003). Trans-scleral delivery of pegaptanib 
was also achieved in rabbits by encapsulating the aptamer 
in poly(lactic-co-glycolic) acid (PLGA) microspheres 
(Carrasquillo et al 2003). The drug was released over a 
period of 20 days and retained activity, providing a promising 
approach for the treatment of retinal and choroidal disorders 
with a dosing frequency of a minimum of every 6 weeks. 
The sustained release of pegaptanib was extended to several 
weeks using PLGA-based microspheres in rabbits (Cook et 
al 2006).
Clinical trials (Table 2)
The initial clinical trials were previously reviewed (Vinores 
2003), but there have been several recent developments. 
Phase I trials with PEG-conjugated pegaptanib sodium began 
in 1998 following US Food and Drug Administration (FDA) 
approval, making it the first aptamer to reach clinical testing. 
This study, conducted by Eyetech Pharmaceuticals, utilized 
dosages ranging from 0.25 to 30 mg/eye in 15 patients with 
wet AMD and demonstrated stabilization or improvement of 
vision in 80% of patients at 3 months and 26.7% showed an 
improvement of 3 lines or more without any toxicity (Eyetech 
Study Group 2002; Guyer et al 2003). Eyetech followed with 
a Phase II study involving multiple intravitreal injections 
with or without photodymanic therapy (PDT), which was 
conducted with 21 patients with subfoveal CNV secondary to 
AMD. In 87.5% of patients receiving only pegaptanib, vision 
stabilized or improved with 25% showing a 3 lines or greater 
improvement, whereas PDT alone was effective in only 
50.5% with only 2.2% showing an improvement of 3 lines or 
more. The level of improvement reached 60% if pegaptanib 
Table 1  Preclinical trials
Species  Effect  Reference
rhesus monkey    no toxic effects, no change in   Drolet et al 
intraocular pressure, no immune   2000 
response to aptamer
rhesus monkey    subcutaneous and intravenous   Tucker et al 
administration effective at maintaining  1999 
adequate plasma levels
guinea pig,  almost total inhibition of veGF-mediated  eyetech Study
rat, mouse,   vascular permeability, reduced veGF-   Group 2002
rabbit    induced corneal angiogenesis, reduced  
Nv in mice with Oir
rats    Suppressed leukostasis and vascular   ishida et al 
leakage in diabetics  2003
Abbreviations: Nv, choroidal neovascularization; Oir, oxygen-induced 
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and PDT were administered together (Guyer et al 2003). Due 
to the potential for pegaptanib to provide a better alternative 
than laser photocoagulation for the treatment of exudative 
(wet) AMD, the FDA granted “fast-track” designation for 
Phase III clinical trials and these trials were underway by 
2002 and involved 1186 patients at 117 centers (Gragoudas 
et al 2004). Pegaptanib has also recently been approved for 
the treatment of wet AMD in Canada (trials launched in 2005) 
and it has been filed for approval in the European Union, 
Australia, Switzerland, and Brazil (Eyetech Pharmaceuticals, 
Inc. 2005). In the US trials, doses of 0.3, 1.0, or 3.0 mg were 
administered and efficacy was demonstrated for all three 
doses without a dose-response relationship. Seventy percent 
of the patients who received 0.3 mg pegaptanib lost fewer 
than 15 letters of visual acuity compared with 55% in sham-
injected controls (Gragoudas et al 2004) and the improvement 
was maintained in a 1-year extension of the trials (Siddiqui 
and Keating 2005). Separate evaluations yielded similar 
results, with 78% of pegaptanib-treated patients showing 
loss of fewer than 15 letters of visual acuity compared with 
54% in patients receiving usual care (VISION Clinical Trial 
Group 2005). The risk of severe loss of visual acuity (>30 
letters) was reduced from 22% in the sham-injected group to 
10% in patients receiving 0.3 mg pegaptanib (Gragoudas et 
al 2004). A separate evaluation found that patients receiving 
usual care were approximately 10 times more likely to suffer 
severe vision loss (29%) than those treated with pegaptanib 
(3%) (VISION Clinical Trial Group 2005). Significantly 
more patients maintained or gained visual acuity if they 
received pegaptanib (33% compared with 23% for sham-
treated controls). Commencing 6 weeks after treatment, 
visual acuity was consistently better in pegaptanib-treated 
patients (Gragoudas et al 2004). In a recent study involving 
40 patients treated with 1 mg intravitreal pegaptanib every 
6 weeks for a duration of 24 weeks, the thickness of the 
central retina decreased from 340 + 24 µm to 280 + 20 µm 
(p = 0.02) and vascular leakage, assessed by fluorescein 
angiograms, decreased from 100% to 54% while stable visual 
acuity was maintained (Emerson et al 2006). Surprisingly, 
when a single eye was treated with pegaptanib, a significant 
macular thickness reduction was noted in the uninjected eye. 
This remote biological effect, possibly occurring through 
systemic absorption, raises concerns about pegaptanib’s 
possible interference with physiological angiogenesis, such 
as coronary collateral vessel formation and wound healing 
(Martin et al 2006).
In a previous evaluation of pegaptanib (Vinores 2003), no 
treatment-related adverse effects were noted. Even at doses 
3- to 10-fold higher than the recommended 0.3 mg/eye dose, 
pegaptanib had an excellent safety profile (Patel et al 2006), 
but some adverse effects have recently been reported with the 
progression of the Phase III trials. Endopthalmitis occurred 
in 1.3% of patients, traumatic injury to the lens in 0.7%, and 
retinal detachment in 0.6%, accounting for the most serious 
adverse effects. Collectively, the adverse events accounted for 
severe loss of visual acuity in 0.1% of patients (Gragoudas 
et al 2004). There was no evidence of a sustained increase in 
intraocular pressure following pegaptanib injection in either 
a short-term (Hariprasad et al 2006) or a long-term setting 
(Gragoudas et al 2004); however, three patients experienced 
severe eye pain that did not effect visual acuity within 2 hours 
of the injection (Liggett et al 2006). Intraocular pressure was 
not elevated, only mild conjunctival inflammation around the 
injection site was noted, and the fundus examination was 
Table 2  Clinical trials
Trial  Dosage range  Duration  Patients  Results  References
Phase i  0.25–30 mg/eye  3 months  15    80% had stabilized or improved vision with   Guyer et al 2002;  
26.7% showing improvement, no toxicity    eyetech Study  
Group 2002
Phase ii    multiple intravitreal   3 months  21  vision stabilized or improved in 87.5%,  Guyer et al 2003;  
injections with or       25% showed 3 lines or greater improvement,   eyetech Study 
without PDT        when combined with PDT, improvement of   Group 2002 
3 lines or greater reached 60%
Phase iii  0.3, 1.0, or 3.0 mg/eye  54 week  1186    efficacy demonstrated for all 3 doses without a   Gragoudas et al 2004;  
dose-dependency relationship, 15%–24%   viSiON Clinical Trial 
improvement (depending on the evaluation) in   Group 2005 
number of patients that lost fewer than 15 letters  
of visual acuity, 2.2–9.7x greater risk of severe visual  
loss (≥30 letters), 10% improvement in patients that  
maintained or gained visual acuity, adverse effects  
accounting for severe loss of visual acuity in 0.1%
Abbreviations: PDT, photodynamic therapy.international Journal of Nanomedicine 2006:1(3) 266
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unchanged; therefore, the etiology of the pain was unclear. 
Also reported were two cases of severe systemic allergic 
responses in association with vitreous administration of 
pegaptanib (Steffensmeier et al 2006). Other adverse effects 
reported following injection of pegaptanib include vitreous 
floaters, vitreous opacities, anterior chamber inflammation, 
reduced visual acuity, corneal edema, blurred vision, and 
dizziness (Doggrell 2005; Thomson CenterWatch 2005).
Combination therapies
Pegaptanib treatment, alone, produces modest effects in the 
treatment of AMD, but it may have added benefit when used 
in combination with other therapies. Intravitreal pegaptanib 
injections for AMD results in stabilization of vision and a 
significant reduction in subretinal fluid thickness, but there 
were no significant anatomical changes in foveal or maximal 
retinal thickness, pigment epithelial detachment, total lesion 
thickness, cystoid macular edema, or CNV membrane 
thickness (Ufret et al 2006), so combining pegaptanib with 
an alternative therapy may help to improve the outcome. In 
two animal models of ocular NV , pegaptanib in combination 
with PDT was more effective at inhibiting and promoting 
regression of NV than either was alone (Ju et al 2006). 
Pegaptanib has also been used successfully in combination 
with PDT for the treatment of AMD (Guyer et al 2003; Vann 
et al 2006). Anti-VEGF therapies, such as pegaptanib, tend 
to be less effective at trying to promote regression of more 
established vessels than at treating AMD in its early stages. 
In addition, PDT upregulates VEGF, potentially leading to 
further complications. In both studies, the combination of 
PDT and pegaptanib treatment improved visual acuity in 
60% of the patients, which exceeded the outcome of either 
mode of therapy alone, and there were no additional safety 
concerns with the combination therapy.
Pegaptanib has also been used sucessfully with 
bevacizumab (Avastin
®), which is a broader spectrum anti-
VEGF treatment, reacting with multiple isoforms rather 
than specifically with VEGF165. Preliminary results suggest 
that bevacizumab has the potential to improve the vision in 
patients who had previously been treated with pegaptanib 
and that pegaptanib can be used to maintain these gains 
while potentially minimizing the toxicity of a pan isoform 
VEGF inhibitor, such as bevacizumab (Tolentino et al 
2006). Preliminary results in a separate study suggest that 
pegaptanib may also be useful when administered subsequent 
to bevacizumab (Hughes and Sang 2006). Patients with occult 
CNV associated with AMD respond better to pegaptanib than 
do patients with classic CNV , raising speculation that another 
isoform of VEGF may be responsible for the development 
of classic CNV (Iyenger et al 2006) and possibly accounting 
for the added benefit of bevacizumab in conjunction with 
pegaptanib.
Outlook
VEGF has been identified as a key molecule in the 
development of ocular NV and vascular permeability, 
making it a good therapeutic target for the treatment of AMD. 
Pegaptanib, an anti-VEGF therapy, is the first agent to be used 
in clinical trials for AMD and the first aptamer used in clinical 
trials. The encouraging preliminary results with animal and 
clinical trials prompted the FDA to grant fast-track status 
for the treatment of AMD. The Phase III clinical trials 
showed modest effects, primarily at stabilization of vision 
and reduction of subretinal fluid. Pegaptanib or other anti-
VEGF therapies were most effective against AMD in the early 
stages and were not particularly effective against the more 
established vessels. When comparing different treatments 
for their efficacy in treating AMD using the Lineweaver-
Burke (LB) linear plot and correcting for differences in 
the initial visual acuity score (VAS), pegaptanib, PDT, and 
anecortave acetate produced a similar slope and ranibizumab 
(Lucentis
®), another anti-VEGF therapy, appeared to be the 
most efficacious treatment, since it is the only treatment 
proven to reverse the slope of visual acuity on a LB plot. If 
all treatments are started at an initial VAS of 60 letters, the 
expected final VAS for ranibizumab would be 69.0 letters, 
for PDT 22.1 letters, for pegaptanib 18.4 letters, and for 
anecortave acetate 21.3 letters (Shah et al 2006). Pegaptanib, 
however, shows greater efficacy when combined with another 
mode of therapy, such as PDT or bevacizumab, and these 
and other combination therapies may be the most promising 
therapeutic approaches for treating AMD.
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